{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:49:42Z","timestamp":1792522182348,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibrodysplasia Ossificans Progressiva (FOP) is a rare genetic disease caused by heterozygous missense mutations in Activin A receptor type I which is also known as Activin-like kinase 2 (ALK2), a type I receptor of Bone Morphogenetic Proteins(BMP). Patients with FOP usually undergo episodic flare-ups and the heterotopic ossification in soft and connective tissues. Molecular mechanism study indicates that Activin A, the ligand which normally transduces Transforming Growth Factor Beta signaling, abnormally activates BMP signaling through ALK2 mutants in FOP, leading to heterotopic bone formation. To date, effective therapies to FOP are unavailable. However, significant advances have recently been made in the development of FOP drugs. In this article, we review the recent advances in understanding the FOP mechanism and drug development, with a focus on the small-molecular and antibody drugs currently in the clinical trials for FOP treatment.<\/jats:p>","DOI":"10.1007\/s11010-022-04446-9","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T04:05:36Z","timestamp":1652155536000},"page":"2327-2334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Recent progress in drug development for fibrodysplasia ossificans progressiva"],"prefix":"10.1007","volume":"477","author":[{"given":"Xinmiao","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6769-9069","authenticated-orcid":false,"given":"Jijun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"issue":"6","key":"4446_CR1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00774-008-0879-8","volume":"26","author":"FS Kaplan","year":"2008","unstructured":"Kaplan FS, Shen Q, Lounev V, Seemann P, Groppe J, Katagiri T et al (2008) Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab 26(6):521\u2013530","journal-title":"J Bone Miner Metab"},{"issue":"Suppl 2","key":"4446_CR2","first-page":"437","volume":"10","author":"RJ Pignolo","year":"2013","unstructured":"Pignolo RJ, Shore EM, Kaplan FS (2013) Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev 10(Suppl 2):437\u2013448","journal-title":"Pediatr Endocrinol Rev"},{"issue":"5","key":"4446_CR3","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1542\/peds.2007-1980","volume":"121","author":"FS Kaplan","year":"2008","unstructured":"Kaplan FS, Xu M, Glaser DL, Collins F, Connor M, Kitterman J et al (2008) Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 121(5):e1295\u2013e1300","journal-title":"Pediatrics"},{"issue":"5","key":"4446_CR4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH et al (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38(5):525\u2013527","journal-title":"Nat Genet"},{"issue":"4","key":"4446_CR5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ajmg.a.32151","volume":"146A","author":"H Furuya","year":"2008","unstructured":"Furuya H, Ikezoe K, Wang L, Ohyagi Y, Motomura K, Fujii N et al (2008) A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A 146A(4):459\u2013463","journal-title":"Am J Med Genet A"},{"issue":"3","key":"4446_CR6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajmg.a.62585","volume":"188","author":"FS Kaplan","year":"2022","unstructured":"Kaplan FS, Groppe JC, Xu M, Towler OW, Grunvald E, Kalunian K et al (2022) An ACVR1(R375P) pathogenic variant in two families with mild fibrodysplasia ossificans progressiva. Am J Med Genet Part A 188(3):806\u2013817","journal-title":"Am J Med Genet Part A"},{"issue":"3","key":"4446_CR7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1097-2765(01)00332-X","volume":"8","author":"M Huse","year":"2001","unstructured":"Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J (2001) The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell 8(3):671\u2013682","journal-title":"Mol Cell"},{"issue":"3","key":"4446_CR8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0092-8674(00)80555-3","volume":"96","author":"M Huse","year":"1999","unstructured":"Huse M, Chen YG, Massague J, Kuriyan J (1999) Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 96(3):425\u2013436","journal-title":"Cell"},{"issue":"1","key":"4446_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ped.14065","volume":"62","author":"N Haga","year":"2020","unstructured":"Haga N, Nakashima Y, Kitoh H, Kamizono J, Katagiri T, Saijo H et al (2020) Fibrodysplasia ossificans progressiva: review and research activities in Japan. Pediatr Int 62(1):3\u201313","journal-title":"Pediatr Int"},{"issue":"3","key":"4446_CR10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/humu.20868","volume":"30","author":"FS Kaplan","year":"2009","unstructured":"Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L et al (2009) Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 30(3):379\u2013390","journal-title":"Hum Mutat"},{"key":"4446_CR11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/BLO.0b013e318126c049","volume":"462","author":"JC Groppe","year":"2007","unstructured":"Groppe JC, Shore EM, Kaplan FS (2007) Functional Modeling of the ACVR1 (R206H) mutation in FOP. Clin Orthop Relat R 462:87\u201392","journal-title":"Clin Orthop Relat R"},{"issue":"2\u20134","key":"4446_CR12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000324230","volume":"194","author":"JC Groppe","year":"2011","unstructured":"Groppe JC, Wu J, Shore EM, Kaplan FS (2011) In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 194(2\u20134):291\u2013295","journal-title":"Cells Tissues Organs"},{"issue":"44","key":"4446_CR13","doi-asserted-by":"crossref","first-page":"36990","DOI":"10.1074\/jbc.M112.365932","volume":"287","author":"A Chaikuad","year":"2012","unstructured":"Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT et al (2012) Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem 287(44):36990\u201336998","journal-title":"J Biol Chem"},{"issue":"12","key":"4446_CR14","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1128\/MCB.01595-12","volume":"33","author":"J Bagarova","year":"2013","unstructured":"Bagarova J, Vonner AJ, Armstrong KA, Borgermann J, Lai CS, Deng DY et al (2013) Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol Cell Biol 33(12):2413\u20132424","journal-title":"Mol Cell Biol"},{"issue":"11","key":"4446_CR15","first-page":"3462","volume":"119","author":"Q Shen","year":"2009","unstructured":"Shen Q, Little SC, Xu MQ, Haupt J, Ast C, Katagiri T et al (2009) The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 119(11):3462\u20133472","journal-title":"J Clin Invest"},{"issue":"29","key":"4446_CR16","doi-asserted-by":"crossref","first-page":"22542","DOI":"10.1074\/jbc.M109.094557","volume":"285","author":"GA Song","year":"2010","unstructured":"Song GA, Kim HJ, Woo KM, Baek JH, Kim GS, Choi JY et al (2010) Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem 285(29):22542\u201322553","journal-title":"J Biol Chem"},{"issue":"6","key":"4446_CR17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1359\/jbmr.091110","volume":"25","author":"M van Dinther","year":"2010","unstructured":"van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J et al (2010) ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Min Res 25(6):1208\u20131215","journal-title":"J Bone Min Res"},{"issue":"50","key":"4446_CR18","doi-asserted-by":"crossref","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M et al (2015) Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci USA 112(50):15438\u201315443","journal-title":"Proc Natl Acad Sci USA"},{"key":"4446_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4358","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L et al (2015) ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aac4358","journal-title":"Sci Transl Med"},{"key":"4446_CR20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12964-015-0104-z","volume":"13","author":"OE Olsen","year":"2015","unstructured":"Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I et al (2015) Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun Signal 13:27","journal-title":"Cell Commun Signal"},{"key":"4446_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3235","author":"J Upadhyay","year":"2017","unstructured":"Upadhyay J, Xie L, Huang L, Das N, Stewart RC, Lyon MC et al (2017) The expansion of heterotopic bone in fibrodysplasia ossificans progressiva is activin A-dependent. J Bone Min Res. https:\/\/doi.org\/10.1002\/jbmr.3235","journal-title":"J Bone Min Res"},{"key":"4446_CR22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bone.2017.06.011","volume":"109","author":"DM Alessi Wolken","year":"2018","unstructured":"Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN (2018) The obligatory role of Activin A in the formation of heterotopic bone in fibrodysplasia ossificans progressiva. Bone 109:210\u2013217","journal-title":"Bone"},{"issue":"6","key":"4446_CR23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/ard.41.6.646-c","volume":"41","author":"JM Connor","year":"1982","unstructured":"Connor JM, Woodrow JC, Evans DAP (1982) Histocompatibility antigens in patients with ectopic ossification due to fibrodysplasia ossificans progressiva. Ann Rheum Dis 41(6):646\u2013647","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4446_CR24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cellsig.2010.10.003","volume":"23","author":"B Bragdon","year":"2011","unstructured":"Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A (2011) Bone morphogenetic proteins: a critical review. Cell Signal 23(4):609\u2013620","journal-title":"Cell Signal"},{"key":"4446_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115472","volume":"138","author":"G Sanchez-Duffhues","year":"2020","unstructured":"Sanchez-Duffhues G, Williams E, Goumans MJ, Heldin CH, Ten Dijke P (2020) Bone morphogenetic protein receptors: structure, function and targeting by selective small molecule kinase inhibitors. Bone 138:115472","journal-title":"Bone"},{"issue":"11","key":"4446_CR26","first-page":"2431","volume":"6","author":"HA Loomans","year":"2016","unstructured":"Loomans HA, Andl CD (2016) Activin receptor-like kinases: a diverse family playing an important role in cancer. Am J Cancer Res 6(11):2431\u20132447","journal-title":"Am J Cancer Res"},{"key":"4446_CR27","doi-asserted-by":"crossref","first-page":"16005","DOI":"10.1038\/boneres.2016.5","volume":"4","author":"S Lin","year":"2016","unstructured":"Lin S, Svoboda KK, Feng JQ, Jiang X (2016) The biological function of type I receptors of bone morphogenetic protein in bone. Bone Res 4:16005","journal-title":"Bone Res"},{"issue":"8","key":"4446_CR28","volume":"13","author":"WM Botello-Smith","year":"2017","unstructured":"Botello-Smith WM, Alsamarah A, Chatterjee P, Xie C, Lacroix JJ, Hao J et al (2017) Polymodal allosteric regulation of type 1 serine\/threonine kinase receptors via a conserved electrostatic lock. PLoS Comput Biol 13(8):e1005711","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"4446_CR29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jbmr.1473","volume":"27","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, Wenkert D, Demertzis JL, DiCarlo EF, Westenberg E, Mumm S (2012) Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1. J Bone Min Res 27(3):729\u2013737","journal-title":"J Bone Min Res"},{"issue":"3","key":"4446_CR30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ejhg.2008.178","volume":"17","author":"R Bocciardi","year":"2009","unstructured":"Bocciardi R, Bordo D, Di Duca M, Di Rocco M, Ravazzolo R (2009) Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur J Hum Genet 17(3):311\u2013318","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"4446_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005005","volume":"4","author":"KA Petrie","year":"2009","unstructured":"Petrie KA, Lee WH, Bullock AN, Pointon JJ, Smith R, Russell RG et al (2009) Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS ONE 4(3):e5005","journal-title":"PLoS ONE"},{"issue":"10","key":"4446_CR32","volume":"9","author":"S Cappato","year":"2021","unstructured":"Cappato S, Traberg R, Gintautiene J, Zara F, Bocciardi RA (2021) case of fibrodysplasia ossificans progressiva associated with a novel variant of the ACVR1 gene. Mol Genet Genomic 9(10):e1774","journal-title":"Mol Genet Genomic"},{"issue":"10","key":"4446_CR33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massague","year":"2012","unstructured":"Massague J (2012) TGF beta signalling in context. Nat Rev Mol Cell Biol 13(10):616\u2013630","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4446_CR34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bone.2017.11.014","volume":"109","author":"H Wang","year":"2018","unstructured":"Wang H, Shore EM, Pignolo RJ, Kaplan FS (2018) Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP). Bone 109:218\u2013224","journal-title":"Bone"},{"issue":"18","key":"4446_CR35","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.3390\/ijms21186498","volume":"21","author":"C Xie","year":"2020","unstructured":"Xie C, Jiang WJ, Lacroix JJ, Luo Y, Hao JJ (2020) Insight into molecular mechanism for activin A-induced bone morphogenetic protein signaling. Int J Mol Sci 21(18):6498","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4446_CR36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio.2007.54","volume":"4","author":"PB Yu","year":"2008","unstructured":"Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA et al (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4(1):33\u201341","journal-title":"Nat Chem Biol"},{"issue":"2","key":"4446_CR37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1021\/cb9002865","volume":"5","author":"J Hao","year":"2010","unstructured":"Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR et al (2010) In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 5(2):245\u2013253","journal-title":"ACS Chem Biol"},{"issue":"1","key":"4446_CR38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1566524016666151222142446","volume":"16","author":"Y Luo","year":"2016","unstructured":"Luo Y, Alsamarah A, Zhang K, Hao J (2016) Development of new therapeutic agents for fibrodysplasia ossificans progressiva. Curr Mol Med 16(1):4\u201311","journal-title":"Curr Mol Med"},{"issue":"15","key":"4446_CR39","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.bmcl.2008.06.052","volume":"18","author":"GD Cuny","year":"2008","unstructured":"Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS et al (2008) Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 18(15):4388\u20134392","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"4446_CR40","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/emboj\/21.7.1743","volume":"21","author":"MJ Goumans","year":"2002","unstructured":"Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21(7):1743\u20131753","journal-title":"EMBO J"},{"issue":"4","key":"4446_CR41","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-10-1451","volume":"71","author":"DD Hu-Lowe","year":"2011","unstructured":"Hu-Lowe DD, Chen EH, Zhang LL, Watson KD, Mancuso P, Lappin P et al (2011) Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Can Res 71(4):1362\u20131373","journal-title":"Can Res"},{"issue":"7","key":"4446_CR42","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1253\/circj.CJ-11-1281","volume":"76","author":"A Chida","year":"2012","unstructured":"Chida A, Shintani M, Nakayama T, Furutani Y, Hayama E, Inai K et al (2012) Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension. Circ J 76(7):1501\u20131804","journal-title":"Circ J"},{"issue":"26","key":"4446_CR43","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1182\/blood-2011-01-330142","volume":"117","author":"SI Cunha","year":"2011","unstructured":"Cunha SI, Pietras K (2011) ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 117(26):6999\u20137006","journal-title":"Blood"},{"issue":"11","key":"4446_CR44","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1016\/j.bmcl.2013.03.113","volume":"23","author":"DW Engers","year":"2013","unstructured":"Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR (2013) Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a] pyrimidine scaffold of Dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorganic Med Chem Lett 23(11):3248","journal-title":"Bioorganic Med Chem Lett"},{"issue":"6","key":"4446_CR45","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/cb300655w","volume":"8","author":"AH Mohedas","year":"2013","unstructured":"Mohedas AH, Xing XC, Armstrong KA, Bullock AN, Cuny GD, Yu PB (2013) Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol 8(6):1291\u20131302","journal-title":"ACS Chem Biol"},{"key":"4446_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128667","author":"T Ullrich","year":"2022","unstructured":"Ullrich T, Arista L, Weiler S, Teixeira-Fouchard S, Broennimann V, Stiefl N et al (2022) Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of activin receptor-like kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva. Bioorg Med Chem Lett. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128667","journal-title":"Bioorg Med Chem Lett"},{"key":"4446_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.95042","author":"E Williams","year":"2021","unstructured":"Williams E, Bagarova J, Kerr G, Xia DD, Place ES, Dey D et al (2021) Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.95042","journal-title":"JCI Insight"},{"issue":"22","key":"4446_CR48","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm060434q","volume":"49","author":"LF Hennequin","year":"2006","unstructured":"Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP et al (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor. J Med Chem 49(22):6465\u20136488","journal-title":"J Med Chem"},{"issue":"8","key":"4446_CR49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJM199608223350812","volume":"335","author":"JM Connor","year":"1996","unstructured":"Connor JM (1996) Fibrodysplasia ossificans progressive: lessons from rare maladies. N Engl J Med 335(8):591\u2013593","journal-title":"N Engl J Med"},{"key":"4446_CR50","unstructured":"Saracatinib Trial TO Prevent FOP (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04307953. Accessed 12 Dec 2021"},{"key":"4446_CR51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2020-136138","volume":"136","author":"YY Chen","year":"2020","unstructured":"Chen YY, Stubbs MC, Pusey M, Wen XM, Collins RJ, Kapilashrami K et al (2020) Characterization of INCB00928, a potent and selective ALK2 inhibitor for the treatment of anemia. Blood 136:52\u201352","journal-title":"Blood"},{"key":"4446_CR52","unstructured":"To assess the efficacy, safety, and tolerability of INCB000928 in participants With Fibrodysplasia Ossificans Progressiva (2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05090891. Accessed 12 Dec 2021"},{"key":"4446_CR53","unstructured":"Study of single-ascending doses of DS-6016a in healthy Japanese subjects (2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04818398. Accessed 12 Dec 2021"},{"key":"4446_CR54","unstructured":"Blueprint medicines presents foundational preclinical data supporting the development of BLU-782, a highly selective ALK2 inhibitor, for the treatment of patients with fibrodysplasia ossificans progressive (2018)"},{"key":"4446_CR55","unstructured":"Safety, tolerability, pharmacokinetics, and food effect of BLU-782 in healthy adults (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03858075. Accessed 14 Dec 2021"},{"key":"4446_CR56","unstructured":"Alison DFA, Riadh L, Michael P, Cori AS, Sara G, Faith S, Sean K, Gordon W, Mark H, Robert S, Rachel S, Morgan L, Pauplis R, Vivek K, Andy B, Timothy L (2019) A clinical update on BLU-782, an investigational ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP). https:\/\/www.blueprintmedicines.com\/wp-content\/uploads\/2019\/09\/Blueprint-Medicines-ASBMR-2019-BLU-782-Poster1.pdf."},{"issue":"11","key":"4446_CR57","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jcph.1638","volume":"60","author":"F Vanhoutte","year":"2020","unstructured":"Vanhoutte F, Liang S, Ruddy M, Zhao A, Drewery T, Wang Y et al (2020) Pharmacokinetics and pharmacodynamics of garetosmab (Anti-activin A): results from a first-in-human phase 1 study. J Clin Pharmacol 60(11):1424\u20131431","journal-title":"J Clin Pharmacol"},{"key":"4446_CR58","unstructured":"A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with fibrodysplasia ossificansprogressiva (2017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03188666. Accessed 16 Dec 2021"},{"issue":"10","key":"4446_CR59","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14728222.2020.1799350","volume":"24","author":"A Ries","year":"2020","unstructured":"Ries A, Schelch K, Falch D, Pany L, Hoda MA, Grusch M (2020) Activin A: an emerging target for improving cancer treatment? Expert Opin Ther Targets 24(10):985\u2013996","journal-title":"Expert Opin Ther Targets"},{"issue":"1\u20132","key":"4446_CR60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2011.04.024","volume":"359","author":"PG Knight","year":"2012","unstructured":"Knight PG, Satchell L, Glister C (2012) Intra-ovarian roles of activins and inhibins. Mol Cell Endocrinol 359(1\u20132):53\u201365","journal-title":"Mol Cell Endocrinol"},{"issue":"1\u20132","key":"4446_CR61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2011.09.031","volume":"359","author":"MP Hedger","year":"2012","unstructured":"Hedger MP, Winnall WR (2012) Regulation of activin and inhibin in the adult testis and the evidence for functional roles in spermatogenesis and immunoregulation. Mol Cell Endocrinol 359(1\u20132):30\u201342","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"4446_CR62","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/pr.2013.159","volume":"74","author":"E Petrakou","year":"2013","unstructured":"Petrakou E, Fotopoulos S, Anagnostakou M, Anatolitou F, Samitas K, Semitekolou M et al (2013) Activin-A exerts a crucial anti-inflammatory role in neonatal infections. Pediatr Res 74(6):675\u2013681","journal-title":"Pediatr Res"},{"issue":"4","key":"4446_CR63","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.201112-2210ED","volume":"185","author":"K Mayer","year":"2012","unstructured":"Mayer K, Buchbinder A, Morty RE (2012) Activin A: a mediator governing inflammation, immunity, and repair. Am J Respir Crit Care Med 185(4):350\u2013352","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"4446_CR64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043797","volume":"7","author":"G Rodriguez-Martinez","year":"2012","unstructured":"Rodriguez-Martinez G, Molina-Hernandez A, Velasco I (2012) Activin A promotes neuronal differentiation of cerebrocortical neural progenitor cells. PLoS ONE 7(8):e43797","journal-title":"PLoS ONE"},{"issue":"1","key":"4446_CR65","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41467-018-02872-2","volume":"9","author":"JB Lees-Shepard","year":"2018","unstructured":"Lees-Shepard JB, Yamamoto M, Biswas AA, Stoessel SJ, Nicholas SE, Cogswell CA et al (2018) Activin-dependent signaling in fibro\/adipogenic progenitors causes fibrodysplasia ossificans progressiva. Nat Commun 9(1):471","journal-title":"Nat Commun"},{"issue":"9","key":"4446_CR66","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI93521","volume":"127","author":"K Hino","year":"2017","unstructured":"Hino K, Horigome K, Nishio M, Komura S, Nagata S, Zhao C et al (2017) Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Invest 127(9):3339\u20133352","journal-title":"J Clin Invest"},{"key":"4446_CR67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bone.2017.12.011","volume":"109","author":"FS Kaplan","year":"2018","unstructured":"Kaplan FS, Zeitlin L, Dunn SP, Benor S, Hagin D, Al Mukaddam M et al (2018) Acute and chronic rapamycin use in patients with fibrodysplasia ossificans progressiva: a report of two cases. Bone 109:281\u2013284","journal-title":"Bone"},{"key":"4446_CR68","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bone.2017.08.010","volume":"109","author":"M Pacifici","year":"2018","unstructured":"Pacifici M (2018) Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial. Bone 109:267\u2013275","journal-title":"Bone"},{"issue":"3","key":"4446_CR69","first-page":"274","volume":"8","author":"TM Underhill","year":"1994","unstructured":"Underhill TM, Cash DE, Linney E (1994) Constitutively active retinoid receptors exhibit interfamily and intrafamily promoter specificity. Mol Endocrinol 8(3):274\u2013285","journal-title":"Mol Endocrinol"},{"issue":"4","key":"4446_CR70","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1083\/jcb.148.4.679","volume":"148","author":"AD Weston","year":"2000","unstructured":"Weston AD, Rosen V, Chandraratna RA, Underhill TM (2000) Regulation of skeletal progenitor differentiation by the BMP and retinoid signaling pathways. J Cell Biol 148(4):679\u2013690","journal-title":"J Cell Biol"},{"issue":"2","key":"4446_CR71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/bdrc.10010","volume":"69","author":"AD Weston","year":"2003","unstructured":"Weston AD, Hoffman LM, Underhill TM (2003) Revisiting the role of retinoid signaling in skeletal development. Birth Defects Res C Embryo Today 69(2):156\u2013173","journal-title":"Birth Defects Res C Embryo Today"},{"issue":"4","key":"4446_CR72","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nm.2334","volume":"17","author":"K Shimono","year":"2011","unstructured":"Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C et al (2011) Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med 17(4):454\u2013460","journal-title":"Nat Med"},{"issue":"9","key":"4446_CR73","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/jbmr.2820","volume":"31","author":"SA Chakkalakal","year":"2016","unstructured":"Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS et al (2016) palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) fibrodysplasia ossificans progressiva (FOP) Mutation. J Bone Min Res 31(9):1666\u20131675","journal-title":"J Bone Min Res"},{"key":"4446_CR74","first-page":"S114","volume":"32","author":"FS Kaplan","year":"2017","unstructured":"Kaplan FS, Hsiao EC, Baujat G, Keen R, Grogan DR, Pignolo RJ (2017) Efficacy and safety of palovarotene in fibrodysplasia ossificans progressiva (FOP): a randomized, placebo-controlled, double-blind study. J Bone Min Res 32:S114\u2013S114","journal-title":"J Bone Min Res"},{"key":"4446_CR75","unstructured":"An efficacy and safety study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (2017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03312634. Accessed 15 Dec 2021"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04446-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T05:58:11Z","timestamp":1727157491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04446-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4446"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04446-9","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"13 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a review article, and no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Its publication has been approved by all co-authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}